Literature DB >> 1821484

Aminooxyacetic acid produces excitotoxic lesions in the rat striatum.

E Urbańska1, C Ikonomidou, M Sieklucka, W A Turski.   

Abstract

The neuropathological, biochemical, and behavioral effects of intrastriatal injection of aminooxyacetic acid (AOAA), a non-specific transaminase inhibitor, were examined in rats. AOAA, 0.1-1 mumol, produced neuronal damage when injected into the striatum of adult rats but failed to damage the striatum of 6-d-old or decorticated rats. AOAA-induced (0.25 mumol-1 mumol) striatal lesions in adult rats displayed excitotoxic characteristics and could be prevented by the N-methyl-D-aspartate (NMDA) receptor antagonists (-)-2-amino-7-phosphono-heptanoate (AP7; 0.25 mumol) or kynurenate (KYNA; 0.5 mumol), but not by the non-NMDA antagonist 2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline (NBQX; 0.25 mumol). AOAA produced a dose-dependent reduction in striatal L-glutamate decarboxylase activity, as measured 14 d following intrastriatal injection, which could also be prevented by AP7 or KYNA, but not by NBQX. These findings suggest that AOAA-induced lesions are preferentially mediated by activation of the NMDA subtype of excitatory amino acid receptors. Behavioral studies revealed that the cataleptic response to haloperidol, 2 mg/kg, was decreased whereas the cataleptic response to arecoline, 15 mg/kg, and morphine, 15 mg/kg, was potentiated in AOAA lesioned animals 14 d following bilateral intrastriatal injections of AOAA, 0.25 and 1 mumol. In rats which received unilateral intrastriatal injection of AOAA, 0.1-1 mumol, apomorphine, 0.5 mg/kg, induced circling towards the lesioned side. Rats which received AP7, 0.25 mumol, or KYNA, 0.5 mumol, coadministered with AOAA, 0.25 mumol, behaved as vehicle-treated controls, while those which received NBQX, 0.25 mumol, and AOAA, 0.25 mumol, had behavioral patterns similar to those subjected to AOAA alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1821484     DOI: 10.1002/syn.890090207

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

1.  Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

2.  NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice.

Authors:  E M Urbańska; E Drelewska; K K Borowicz; P Błaszczak; Z Kleinrok; S J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Authors:  Tomasz Kocki; Sebastian Wnuk; Renata Kloc; Janusz Kocki; Björn Owe-Larsson; Ewa M Urbanska
Journal:  J Neural Transm (Vienna)       Date:  2011-06-10       Impact factor: 3.575

4.  MRS study of glutamate metabolism in cultured neurons/glia.

Authors:  U Sonnewald; L R White; E Odegård; N Westergaard; I J Bakken; J Aasly; G Unsgård; A Schousboe
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

5.  L-alpha-aminoadipate inhibits kynurenate synthesis in rat brain hippocampus and tissue culture.

Authors:  Y F Chang; R K Cauley; J D Chang; V V Rao
Journal:  Neurochem Res       Date:  1997-07       Impact factor: 3.996

6.  Novel aspect of ketone action: β-hydroxybutyrate increases brain synthesis of kynurenic acid in vitro.

Authors:  Iwona Chmiel-Perzyńska; Renata Kloc; Adam Perzyński; Sławomir Rudzki; Ewa M Urbańska
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

7.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

Review 8.  Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology.

Authors:  L Turski; W A Turski
Journal:  Experientia       Date:  1993-12-15

9.  Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.

Authors:  Iwona Chmiel-Perzyńska; Adam Perzyński; Bartosz Olajossy; Paulina Gil-Kulik; Janusz Kocki; Ewa M Urbańska
Journal:  J Diabetes Res       Date:  2019-10-13       Impact factor: 4.011

Review 10.  Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?

Authors:  Aleksandra Ostapiuk; Ewa M Urbanska
Journal:  CNS Neurosci Ther       Date:  2021-12-03       Impact factor: 5.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.